.jpg?format=webp&quality=80&width=3840)
The study is a phase 3 trial investigating the efficacy and safety of an investigational bivalent RSV prefusion F protein-based vaccine in adults aged 60 years or older. Participants were randomly assigned to receive either the vaccine or placebo. The primary endpoints were vaccine efficacy against seasonal RSV-associated lower respiratory tract illness with at least two or at least three signs or symptoms, and the secondary endpoint was vaccine efficacy against RSV-associated acute respiratory illness. The interim analysis showed that the vaccine prevented RSV-associated lower respiratory tract illness and RSV-associated acute respiratory illness in adults without evident safety concerns. The incidence of local reactions was higher with the vaccine, but systemic events were similar between the vaccine and placebo groups. Similar rates of adverse events were reported in both groups.
Like
Save
Share